NCT01089608 is a Phase 2 clinical trial of Azithromycin in Blepharitis, sponsored by Laboratoires Thea.

Who is sponsoring NCT01089608?

NCT01089608 is sponsored by Laboratoires Thea.

What drugs are being tested in NCT01089608?

Interventions in NCT01089608: Azithromycin, Povidone.

What condition does NCT01089608 study?

NCT01089608 studies Blepharitis.

Is NCT01089608 still recruiting?

NCT01089608 is currently completed. Last updated 3 November 2014.

Are results published for NCT01089608?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2014-11-03 · How we verify

NCT01089608

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis (Pilot Phase II Clinical Study, Multicentre, Randomised, Double Masked, Comparative, 2 X 40 Patients)

Completed Phase 2 Results posted Last updated 3 November 2014

What this trial tests

Phase 2 trial testing Azithromycin in Blepharitis in 93 participants. Completed in 1 June 2012.

Timeline

1 March 2010

Primary endpoint
1 June 2012

1 June 2012

Quick facts

Lead sponsor	Laboratoires Thea
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	93
Start date	1 March 2010
Primary completion	1 June 2012
Estimated completion	1 June 2012
Sites	1 location across France

Drugs / interventions tested

Azithromycin (azithromycin) — full drug profile →
Povidone (CROSPOVIDONE) — full drug profile →

Conditions studied

Blepharitis — all drugs for Blepharitis →

Sponsor

Laboratoires Thea — full company profile →

Who can join

18 and older, any sex, with Blepharitis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Visual Analogue Scale (VAS - Ranges 0-100 mm)
Time frame: Baseline and D63 (D63 minus baseline)
The primary objective is to evaluate the efficacy of the treatment by the change from baseline (Day 0) to Day 63 (± 3 Days) of the global ocular discomfort (Visual Analogue Scale) (Decrease of VAS value = better outcome)

Sponsor's own description

The primary objective of this study is to demonstrate the efficacy of T1225 eye drops versus placebo eye drops on the global ocular discomfort (VAS).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Azithromycin

Trials testing the same drug.

NCT07306234 — Doxycycline vs. Macrolide for MRMP (DOMINO) · Phase 4 · not yet recruiting
NCT06461429 — PLatform for Adaptive Trials In Perinatal UnitS - [Core Protocol] · NA · not yet recruiting
NCT07164131 — Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lacta · Phase 4 · recruiting
NCT07052942 — Individualizing Treatment for Asthma in Primary Care (Full Study) · Phase 4 · recruiting
NCT07213765 — Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease · Phase 4 · recruiting

Other recruiting trials for Blepharitis

Currently open trials in the same condition.

NCT06371300 — Photobiomodulation With REd vs BluE Light (REBEL) · NA · recruiting
NCT06054217 — Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex · Phase 2 · active not recruiting
NCT04603222 — Evaluation of SUMMIT BRUSH in Treatment of Blepharitis · NA · recruiting

Other Laboratoires Thea trials

Trials by the same sponsor.

NCT07169695 — A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vern · Phase 2 · recruiting
NCT07234318 — A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyc · active not recruiting
NCT07234292 — Evaluation of Patient Satisfaction With Blephaderm as a Complementary Care in Post-eyelid Surgery. · not yet recruiting
NCT07007702 — Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye Dise · completed
NCT06375499 — Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome. · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01089608 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Laboratoires Thea
Last refreshed: 3 November 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01089608.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing